
Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
HOUSTON, March 06, 2025 — Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the […]